Related Experiment Video
Updated: Apr 28, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Thromboembolism in atrial fibrillation
Jan Menke1, Lars Lüthje, Andreas Kastrup
1University Hospital, Göttingen, Germany. menke-j@t-online.de
Insights
Atrial fibrillation significantly increases the risk of thromboembolism, including stroke and limb ischemia. Guideline-adherent antithrombotic therapy with aspirin or warfarin effectively reduces these risks.
Area of Science:
- Cardiology
- Vascular Medicine
- Thrombosis Research
Background:
- Atrial fibrillation is a major risk factor for systemic thromboembolism.
- Thromboembolic events in atrial fibrillation include stroke, mesenteric ischemia, and limb ischemia.
Purpose of the Study:
- To provide an overview of thromboembolic disease as a complication of atrial fibrillation.
- To review current and emerging therapeutic strategies for risk reduction.
Main Methods:
- Systematic literature search of PubMed, Embase, and Cochrane databases (1986-2009).
- Extraction of data from 10 evidence-based guidelines and 61 additional sources.
Main Results:
- Atrial fibrillation increases annual stroke risk by 2.3% (30% lethality).
- Annual incidence of acute mesenteric ischemia is 0.14% (70% lethality), and acute limb ischemia is 0.4% (16% lethality).
- Stroke accounts for approximately 80% of embolism-related deaths.
Conclusions:
- Atrial fibrillation predisposes patients to significant thromboembolic risks.
- Early diagnosis and guideline-adherent antithrombotic therapy (aspirin, warfarin) are crucial for risk reduction.
- Novel anticoagulants and self-monitoring of international normalized ratio (INR) represent future therapeutic directions.
Abstract:
Thromboembolism is a severe complication in atrial fibrillation. This overview presents thromboembolic disease as a single entity, ranging from stroke through mesenteric ischemia to acute limb ischemia. The PubMed, Embase, and Cochrane databases were systematically searched for the terms "atrial fibrillation" and "thromboembolism" in reports published from January 1986 to September 2009. The information of 10 evidence-based practice guideline documents and 61 further sources was systematically extracted. In atrial fibrillation, the average annual stroke risk is increased by 2.3% (lethality 30%). The annual incidence of acute mesenteric ischemia is 0.14% (lethality 70%), and that of acute limb ischemia is 0.4% (lethality 16%). In total, approximately 80% of embolism-related deaths are from stroke and 20% from other systemic thromboembolism. The ischemic symptoms generally have an acute onset but may mimic other diseases, particularly in mesenteric ischemia. Early diagnosis and treatment can limit or even prevent tissue infarction. Guideline-recommended therapy with aspirin or warfarin reduces the thromboembolic risk. Suitable patients may optimize their warfarin therapy by self-monitoring of the international normalized ratio (INR). New oral and parenteral anticoagulants with more stable pharmacokinetics are being developed. In conclusion, atrial fibrillation predisposes to thromboembolism. If ischemic stroke or systemic thromboembolism occurs, early diagnosis and treatment can improve outcomes. The thromboembolic risks are reduced by guideline-adherent antithrombotic therapy with warfarin or aspirin. Future directions may include self-monitoring of the international normalized ratio and novel anticoagulants.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism I: Introduction

